1.
Product Overview
2.
Research Methodology
3.
Executive Summary
4.
Impact of COVID-19 on Global Precision Psychiatry Market
5.
Voice of Customer
6. Global Precision
Psychiatry Market Outlook
6.1.
Market Size & Forecast
6.1.1. By Value
6.2.
Market Share & Forecast
6.2.1. By Biomarkers (Genetic v/s Protein)
6.2.2. By Sample (Blood Based v/s Non-Blood-Based)
6.2.2.1.
By Non-Blood-Based
(Saliva, Urine, Cerebral Spinal Fluid, Others)
6.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray,
Immunoassay, Others)
6.2.4. By Application (Alzheimer’s Disease, Parkinson’s Disease, Autism,
Depression, Others)
6.2.5. By End User (Hospital & Clinics, Academic & Research
Institutions, Others)
6.2.6. By Company (2021)
6.2.7. By Region
6.3.
Product Market Map
7. North America
Precision Psychiatry Market Outlook
7.1.
Market Size & Forecast
7.1.1. By Value
7.2.
Market Share & Forecast
7.2.1. By Biomarkers (Genetic v/s Protein)
7.2.2. By Sample (Blood Based v/s Non-Blood-Based)
7.2.2.1.
By Non-Blood-Based
(Saliva, Urine, Cerebral Spinal Fluid, Others)
7.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray,
Immunoassay, Others)
7.2.4. By Application (Alzheimer’s Disease, Parkinson’s Disease, Autism,
Depression, Others)
7.2.5. By End User (Hospital & Clinics, Academic & Research
Institutions, Others)
7.2.6. By Country
7.3.
North America: Country Analysis
7.3.1. United States
Precision Psychiatry Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Biomarker
7.3.1.2.2.
By Sample
7.3.1.2.3.
By Technology
7.3.1.2.4.
By Application
7.3.1.2.5.
By End User
7.3.2. Mexico Precision
Psychiatry Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Biomarker
7.3.2.2.2.
By Sample
7.3.2.2.3.
By Technology
7.3.2.2.4.
By Application
7.3.2.2.5.
By End User
7.3.3. Canada Precision
Psychiatry Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Biomarker
7.3.3.2.2.
By Sample
7.3.3.2.3.
By Technology
7.3.3.2.4.
By Application
7.3.3.2.5.
By End User
8. Europe Precision
Psychiatry Market Outlook
8.1.
Market Size & Forecast
8.1.1. By Value
8.2.
Market Share & Forecast
8.2.1. By Biomarkers (Genetic v/s Protein)
8.2.2. By Sample (Blood Based v/s Non-Blood-Based)
8.2.2.1.
By Non-Blood-Based
(Saliva, Urine, Cerebral Spinal Fluid, Others)
8.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray,
Immunoassay, Others)
8.2.4. By Application (Alzheimer’s Disease, Parkinson’s Disease, Autism,
Depression, Others)
8.2.5. By End User (Hospital & Clinics, Academic & Research
Institutions, Others)
8.2.6. By Country
8.3.
Europe: Country Analysis
8.3.1. France Precision
Psychiatry Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Biomarker
8.3.1.2.2.
By Sample
8.3.1.2.3.
By Technology
8.3.1.2.4.
By Application
8.3.1.2.5.
By End User
8.3.2. Germany Precision
Psychiatry Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Biomarker
8.3.2.2.2.
By Sample
8.3.2.2.3.
By Technology
8.3.2.2.4.
By Application
8.3.2.2.5.
By End User
8.3.3. United Kingdom
Precision Psychiatry Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Biomarker
8.3.3.2.2.
By Sample
8.3.3.2.3.
By Technology
8.3.3.2.4.
By Application
8.3.3.2.5.
By End User
8.3.4. Italy Precision
Psychiatry Market Outlook
8.3.4.1.
Market Size & Forecast
8.3.4.1.1.
By Value
8.3.4.2.
Market Share & Forecast
8.3.4.2.1.
By Biomarker
8.3.4.2.2.
By Sample
8.3.4.2.3.
By Technology
8.3.4.2.4.
By Application
8.3.4.2.5.
By End User
8.3.5. Spain Precision
Psychiatry Market Outlook
8.3.5.1.
Market Size & Forecast
8.3.5.1.1.
By Value
8.3.5.2.
Market Share & Forecast
8.3.5.2.1.
By Biomarker
8.3.5.2.2.
By Sample
8.3.5.2.3.
By Technology
8.3.5.2.4.
By Application
8.3.5.2.5.
By End User
9. Asia-Pacific
Precision Psychiatry Market Outlook
9.1.
Market Size & Forecast
9.1.1. By Value
9.2.
Market Share & Forecast
9.2.1. By Biomarkers (Genetic v/s Protein)
9.2.2. By Sample (Blood Based v/s Non-Blood-Based)
9.2.2.1.
By Non-Blood-Based
(Saliva, Urine, Cerebral Spinal Fluid, Others)
9.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray,
Immunoassay, Others)
9.2.4. By Application (Alzheimer’s Disease, Parkinson’s Disease, Autism,
Depression, Others)
9.2.5. By End User (Hospital & Clinics, Academic & Research
Institutions, Others)
9.2.6. By Country
9.3.
Asia-Pacific: Country Analysis
9.3.1. China Precision
Psychiatry Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Biomarker
9.3.1.2.2.
By Sample
9.3.1.2.3.
By Technology
9.3.1.2.4.
By Application
9.3.1.2.5.
By End User
9.3.2. India Precision Psychiatry
Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Biomarker
9.3.2.2.2.
By Sample
9.3.2.2.3.
By Technology
9.3.2.2.4.
By Application
9.3.2.2.5.
By End User
9.3.3. South Korea
Precision Psychiatry Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Biomarker
9.3.3.2.2.
By Sample
9.3.3.2.3.
By Technology
9.3.3.2.4.
By Application
9.3.3.2.5.
By End User
9.3.4. Japan Precision
Psychiatry Market Outlook
9.3.4.1.
Market Size & Forecast
9.3.4.1.1.
By Value
9.3.4.2.
Market Share & Forecast
9.3.4.2.1.
By Biomarker
9.3.4.2.2.
By Sample
9.3.4.2.3.
By Technology
9.3.4.2.4.
By Application
9.3.4.2.5.
By End User
9.3.5. Australia Precision
Psychiatry Market Outlook
9.3.5.1.
Market Size & Forecast
9.3.5.1.1.
By Value
9.3.5.2.
Market Share & Forecast
9.3.5.2.1.
By Biomarker
9.3.5.2.2.
By Sample
9.3.5.2.3.
By Technology
9.3.5.2.4.
By Application
9.3.5.2.5.
By End User
10. South America
Precision Psychiatry Market Outlook
10.1.
Market Size & Forecast
10.1.1. By Value
10.2.
Market Share & Forecast
10.2.1. By Biomarkers (Genetic v/s Protein)
10.2.2. By Sample (Blood Based v/s Non-Blood-Based)
10.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
10.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray,
Immunoassay, Others)
10.2.4. By Application (Alzheimer’s Disease, Parkinson’s Disease, Autism,
Depression, Others)
10.2.5. By End User (Hospital & Clinics, Academic & Research
Institutions, Others)
10.2.6. By Country
10.3.
South America: Country Analysis
10.3.1. Brazil Precision
Psychiatry Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1.
By Biomarker
10.3.1.2.2.
By Sample
10.3.1.2.3.
By Technology
10.3.1.2.4.
By Application
10.3.1.2.5.
By End User
10.3.2. Argentina Precision
Psychiatry Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1.
By Biomarker
10.3.2.2.2.
By Sample
10.3.2.2.3.
By Technology
10.3.2.2.4.
By Application
10.3.2.2.5.
By End User
10.3.3. Colombia Precision
Psychiatry Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1.
By Biomarker
10.3.3.2.2.
By Sample
10.3.3.2.3.
By Technology
10.3.3.2.4.
By Application
10.3.3.2.5.
By End User
11. Middle East and
Africa Precision Psychiatry Market Outlook
11.1.
Market Size & Forecast
11.1.1. By Value
11.2.
Market Share & Forecast
11.2.1. By Biomarkers (Genetic v/s Protein)
11.2.2. By Sample (Blood Based v/s Non-Blood-Based)
11.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
11.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray,
Immunoassay, Others)
11.2.4. By Application (Alzheimer’s Disease, Parkinson’s Disease, Autism,
Depression, Others)
11.2.5. By End User (Hospital & Clinics, Academic & Research
Institutions, Others)
11.2.6. By Country
11.3.
MEA: Country Analysis
11.3.1. South Africa
Precision Psychiatry Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1.
By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1.
By Biomarker
11.3.1.2.2.
By Sample
11.3.1.2.3.
By Technology
11.3.1.2.4.
By Application
11.3.1.2.5.
By End User
11.3.2. Saudi Arabia
Precision Psychiatry Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1.
By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1.
By Biomarker
11.3.2.2.2.
By Sample
11.3.2.2.3.
By Technology
11.3.2.2.4.
By Application
11.3.2.2.5.
By End User
11.3.3. UAE Precision
Psychiatry Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1.
By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1.
By Biomarker
11.3.3.2.2.
By Sample
11.3.3.2.3.
By Technology
11.3.3.2.4.
By Application
11.3.3.2.5.
By End User
11.3.4. Egypt Precision
Psychiatry Market Outlook
11.3.4.1. Market Size & Forecast
11.3.4.1.1.
By Value
11.3.4.2. Market Share & Forecast
11.3.4.2.1.
By Biomarker
11.3.4.2.2.
By Sample
11.3.4.2.3.
By Technology
11.3.4.2.4.
By Application
11.3.4.2.5.
By End User
11.3.5. Turkey Precision
Psychiatry Market Outlook
11.3.5.1. Market Size & Forecast
11.3.5.1.1.
By Value
11.3.5.2. Market Share & Forecast
11.3.5.2.1.
By Biomarker
11.3.5.2.2.
By Sample
11.3.5.2.3.
By Technology
11.3.5.2.4.
By Application
11.3.5.2.5.
By End User
12.
Market Dynamics
12.1.
Drivers
12.2.
Challenges
13.
Market Trends & Developments
14.
Competitive Landscape
14.1.
Altimate Healthcare
14.2.
PsyProtix, Inc
14.3.
Cerebral-Alto Nanoscience
14.4.
Precision Psychiatric Services, Inc
14.5.
Tempus Labs, Inc.
14.6.
Curis AI Inc.
15. Strategic Recommendations